Medtronic revises labeling for spinal cord stimulation device

The FDA approved revised commercial labeling for Medtronic’s Intellis Platform with Differential Target Multiplexed programming.

Advertisement

The new labeling will include outcomes from a study showing “superior back pain relief” compared to conventional spinal cord stimulation, according to a March 17 news release.

Eighty-four percent of patients in the 12-month randomized controlled study reported at least 50 percent pain relief after being treated with the DTM system. Fifty-one percent of patients reported the same pain relief using a conventional spinal cord stimulator.

More articles on physicians:
There were 226 ASCs opened in 2019 & 3 more MedPAC 2021 report highlights
Missouri medical group breaks ground on outpatient surgery center
Bundled payments in ASCs: Good business or a race to the bottom?

Advertisement

Next Up in Outpatient Spine

Advertisement

Comments are closed.